β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer

Programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) checkpoint blocking antibodies have been shown to be a powerful immune checkpoint blockade (ICB) therapy for patients with cancer. However, patients quickly develop resistance to immunotherapy. β-glucan, an immune adjuvant, has been found to stimulate in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Mengjie, Bai, Yu, Pei, Jiaxin, Li, Dongqing, Pu, Xiaolin, Zhu, Wenyu, Xia, Lei, Qi, Chunjian, Jiang, Hua, Ning, Yongling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084312/
https://www.ncbi.nlm.nih.gov/pubmed/35548349
http://dx.doi.org/10.3389/fphar.2022.887457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084312/
https://www.ncbi.nlm.nih.gov/pubmed/35548349
http://dx.doi.org/10.3389/fphar.2022.887457

Ejemplares similares